Literature DB >> 34790967

Impact of Potentially Unwarranted Intravenous Antibiotics Targeting Pulmonary Infections in Acute Decompensated Heart Failure.

Sara Wu1, Maryam Alikhil1, Rochelle Forsyth1, Bryan Allen1.   

Abstract

BACKGROUND: Acute decompensated heart failure (ADHF) can present similarly to pulmonary infections. The additional volume and sodium received from intravenous antibiotics (IVAB) can be counterproductive, especially when strong evidence of infection is lacking.
OBJECTIVE: The objective was to evaluate the impact of potentially unwarranted IVAB on clinical outcomes in patients with ADHF.
METHODS: This multicenter, retrospective, cohort study evaluated adults admitted with ADHF, a chest radiograph within 24 hours, B-natriuretic peptide >100 pg/mL, and either received no IVAB or IVAB for at least 48 hours. Subjects with recent antibiotics, justification for antibiotics, or transferred to the intensive care unit (ICU) within 24 hours of admission were excluded. The primary outcome was hospital length of stay (LOS). Secondary outcomes included utilization of loop diuretics, administration of fluid and sodium, mortality, and 30-day readmissions.
RESULTS: Out of 240 subjects included, 120 received IVAB. LOS was significantly longer in the IVAB group (5.12 days vs 3.73 days; P < .001). LOS remained significantly longer in the IVAB group in a propensity score matched cohort (5.26 days vs 3.70 days; P < .001). The IVAB group received more volume and sodium from intravenous fluids (P < .001). ICU admission greater than 24 hours after admission was higher with IVAB (20% vs 7.5%; P = .049). No significant differences in total loop diuretics, intubation rate, mortality, and 30-day readmissions were identified.
CONCLUSION: ADHF patients who received potentially unwarranted IVAB had longer hospital LOS and were more likely to be admitted to the ICU after 24 hours of hospitalization.
© The Author(s) 2021.

Entities:  

Keywords:  COPD; antibiotics; congestive heart failure; infectious disease; pneumonia; prescribing patterns

Year:  2021        PMID: 34790967      PMCID: PMC8592242          DOI: 10.1177/87551225211038020

Source DB:  PubMed          Journal:  J Pharm Technol        ISSN: 1549-4810


  13 in total

1.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

Authors:  M S Niederman; L A Mandell; A Anzueto; J B Bass; W A Broughton; G D Campbell; N Dean; T File; M J Fine; P A Gross; F Martinez; T J Marrie; J F Plouffe; J Ramirez; G A Sarosi; A Torres; R Wilson; V L Yu
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

2.  Trends in Outcomes, Financial Burden, and Mortality for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in the United States from 2002 to 2010.

Authors:  Chetna Jinjuvadia; Raxitkumar Jinjuvadia; Chaitanya Mandapakala; Navin Durairajan; Suthat Liangpunsakul; Ayman O Soubani
Journal:  COPD       Date:  2016-07-15       Impact factor: 2.409

3.  Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005-2014): ARIC Study Community Surveillance.

Authors:  Patricia P Chang; Lisa M Wruck; Eyal Shahar; Joseph S Rossi; Laura R Loehr; Stuart D Russell; Sunil K Agarwal; Suma H Konety; Carlos J Rodriguez; Wayne D Rosamond
Journal:  Circulation       Date:  2018-03-08       Impact factor: 29.690

4.  Global Public Health Burden of Heart Failure.

Authors:  Gianluigi Savarese; Lars H Lund
Journal:  Card Fail Rev       Date:  2017-04

5.  Predictors of Hospital Length of Stay in Patients with Exacerbations of COPD: A Cohort Study.

Authors:  José M Quintana; Anette Unzurrunzaga; Susana Garcia-Gutierrez; Nerea Gonzalez; Iratxe Lafuente; Marisa Bare; Nerea Fernandez de Larrea; Francisco Rivas; Cristóbal Esteban
Journal:  J Gen Intern Med       Date:  2014-12-04       Impact factor: 5.128

6.  Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.

Authors:  Paul A Heidenreich; Nancy M Albert; Larry A Allen; David A Bluemke; Javed Butler; Gregg C Fonarow; John S Ikonomidis; Olga Khavjou; Marvin A Konstam; Thomas M Maddox; Graham Nichol; Michael Pham; Ileana L Piña; Justin G Trogdon
Journal:  Circ Heart Fail       Date:  2013-04-24       Impact factor: 8.790

7.  Survival after the onset of congestive heart failure in Framingham Heart Study subjects.

Authors:  K K Ho; K M Anderson; W B Kannel; W Grossman; D Levy
Journal:  Circulation       Date:  1993-07       Impact factor: 29.690

Review 8.  Acute decompensated heart failure: contemporary medical management.

Authors:  Susan M Joseph; Ari M Cedars; Gregory A Ewald; Edward M Geltman; Douglas L Mann
Journal:  Tex Heart Inst J       Date:  2009

Review 9.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Authors:  Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski
Journal:  Am J Respir Crit Care Med       Date:  2007-05-16       Impact factor: 21.405

10.  Adverse Outcomes Associated With Potentially Inappropriate Antibiotic Use in Heart Failure Admissions.

Authors:  Jason Frisbee; R Eric Heidel; Mark S Rasnake
Journal:  Open Forum Infect Dis       Date:  2019-05-08       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.